Quick Answer
SUTRO BIOPHARMA, INC. reported Stockholders Equity of -$132.45 million for the year ending 2025.
- SUTRO BIOPHARMA, INC. showed a decrease of -397.0% in Stockholders Equity from 2024 to 2025.
- This data is from SUTRO BIOPHARMA, INC.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$120.75 million | Q2 2018: -$132.02 million | Q3 2018: -$141.43 million | Q1 2019: $130.72 million | Q2 2019: $119.56 million | Q3 2019: $109.91 million | Q1 2020: $82.09 million | Q2 2020: $206.76 million | Q3 2020: $244.12 million | Q1 2021: $307.34 million | Q2 2021: $307.50 million | Q3 2021: $283.58 million | Q1 2022: $220.37 million | Q2 2022: $209.06 million | Q3 2022: $229.73 million | Q1 2023: $185.41 million | Q2 2023: $154.72 million | Q3 2023: $112.43 million | Q1 2024: $98.02 million | Q2 2024: $152.18 million | Q3 2024: $111.22 million | Q1 2025: -$25.81 million | Q2 2025: -$32.11 million | Q3 2025: -$87.27 million.
- Over the full 11 years of available data (2015 to 2025), SUTRO BIOPHARMA, INC.'s Stockholders Equity has declined by 41.1%.
- Historical annual values: Fiscal year 2025: -$132.45 million | Fiscal year 2024: $44.60 million | Fiscal year 2023: $149.65 million | Fiscal year 2022: $217.05 million | Fiscal year 2021: $252.56 million | Fiscal year 2020: $332.05 million | Fiscal year 2019: $97.79 million | Fiscal year 2018: $131.54 million | Fiscal year 2017: -$109.00 million | Fiscal year 2016: -$90.90 million | Fiscal year 2015: -$93.90 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: